Evidence map›Paper›PMID 42627174›Full record

ArticleMicrobiology spectrum2026

Development and validation of a high-throughput agglutination assay for O-serogrouping clinical

Ritu Shastry, Wenchi Shang, Sarah Janssen, Sarah Tete, Elizabeth Garcia Dominguez, Germie van den Dobbelsteen, Todd Davies, Brian Morrow

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ritu ShastryBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
Wenchi ShangBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
Sarah JanssenDiscovery and Manufacturing Statistics, Johnson & Johnson Innovative Medicine, Archimedesweg, Leiden, the Netherlands.
Sarah TeteBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Archimedesweg, Leiden, the Netherlands.
Elizabeth Garcia DominguezBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
Germie van den DobbelsteenBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Archimedesweg, Leiden, the Netherlands.ORCID 0009-0009-3703-9842
Todd DaviesBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.
Brian MorrowBacterial Vaccines Discovery and Early Development, Johnson & Johnson Innovative Medicine, Raritan, New Jersey, USA.ORCID 0009-0009-5659-6396

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate O-serotyping of

Indexed as

Agglutination TestsEscherichia coliEscherichia coli InfectionsHigh-Throughput Screening AssaysO AntigensSerotypingHumansSensitivity and SpecificitySerogroupO Antigensclinical validationEscherichia colihigh-throughput O-serotyping

Identifiers

PMID42627174
PMCPMC13689272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.